Drugs / MenACWY-CRM Vaccine
last change Oct 2014 re-read 2 minutes ago

MenACWY-CRM Vaccine

also known as MenACWY-CRM

Vaccine

Developed for
meningococcemia · meningococcal meningitis
Investigated by
Novartis Vaccines

Trials 1 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00262028 Apr 2005 → Nov 2006 meningococcemia Novartis Vaccines Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01466387 Comparator Nov 2011 → Apr 2012 Japanese encephalitis, meningococcal meningitis, rabies, typhoid fever +1 Novartis Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as MenACWY-CRM Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00262028
1

NCT01466387

Known as MenACWY-CRM “quadrivalent meningococcal glycoconjugate ACWY-CRM vaccine (MenACWY-CRM)” PMID 25308927 Oct 2014
Modality Vaccine “MenACWY-CRM VaccineNCT00262028